Management of Cardiovascular Risk Factors

This study is currently recruiting participants.

Verified by AstraZeneca, February 2009

First Received: February 19, 2009 Last Updated: February 24, 2009 History of Changes

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00848380

Purpose

This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia

Condition
Cardiovascular Risk Factors Cardiovascular Diseases

Study Type:	Observational
Study Design:	Case Control, Retrospective
Official Title:	Management of Cardiovascular Risk Factors

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. [ Time Frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	4700
Study Start Date:	February 2009
Estimated Study Completion Date:	July 2009

Groups/Cohorts
1 Patients with hypertension and hyperlipidemia and other CV risk factors

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Patients with hypertension and hyperlipidemia and other CV risk factors

Criteria

Inclusion Criteria:

Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
Patients received during the observation time new cholesterol lowering and hypertension treatment

Exclusion Criteria:

Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00848380

Contacts

Contact: AstraZeneca Switzerland Clinical Study Information

041 7257575

madeleine.billeter@astrazeneca.com

Show 36 Study Locations

Sponsors and Collaborators

AstraZeneca

More Information

No publications provided

Responsible Party:	AstraZeneca Pharmaceuticals ( Madeleine Billeter MD, Medical Affairs & Regulatory Director )
Study ID Numbers:	NIS-CCH-DUM-2008/2
Study First Received:	February 19, 2009
Last Updated:	February 24, 2009
ClinicalTrials.gov Identifier:	NCT00848380 History of Changes
Health Authority:	Switzerland: Ethikkommission

Keywords provided by AstraZeneca:

Hypertension
hyperlipidemia

Study placed in the following topic categories:

Hyperlipidemias
Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 30, 2009